RPRX
RoyaltyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Bull case: successful tuck-in acquisitions or above-consensus royalty inflows plus benign interest rates lift NAV multiples toward the analyst high; clinical/regulatory milestones for high-value assets are realized, supporting upside to or above the analyst high of $58.8 [#SERP-3].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Adverse clinical/regulatory outcomes for key royalty assets
Momentum
45
Value
63
Sentiment
29
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $46.34 · Bull $58.80 · Bear $38.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-31 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $61.71
Why
Momentum45 · Δ7d -1.2
Value63 · Δ7d -0.2
Sentiment29 · Δ7d -5.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
45
26% active weight
Current posture
7d trendFlat
Δ7d
-1.2
Δ21d
-33.8
Value
63
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.1
Sentiment
29
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.2
Δ21d
-4.4
Why this grade
Composite grade D. Momentum 44.6 / Value 63.0 / Sentiment 28.7
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$33B
Beta
0.41
Shares Out
443.27M
P/E (TTM)
22.7
P/S (TTM)
9.74
P/FCF (TTM)
40.35
Rev YoY
+11.0%
EPS YoY
+62.8%
Gross Margin
-
Op Margin
+65.2%
Net Debt
$8.33B
Current Ratio
2.66
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology